{
    "clinical_study": {
        "@rank": "25150", 
        "arm_group": {
            "arm_group_label": "LAmbre closure system", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The aim of this study is to assess the efficacy, safety and performance of LAmbre left\n      atrial appendage closure system in patients with non-valvular atrial fibrillation who cannot\n      be treated with Warfarin."
        }, 
        "brief_title": "Safety and Efficacy Study of LAmbre LAA Closure Device for Treating AF Patients Who Cannot Take Warfarin", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Atrial Fibrillation", 
        "condition_browse": {
            "mesh_term": "Atrial Fibrillation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age>=18, CHADS2 score>=1\n\n          -  Patients cannot be treated long-term with Warfarin\n\n          -  Eligible for clopidogrel and aspirin\n\n          -  Provide written informed consent and agree to comply with required follow-ups\n\n        Exclusion Criteria:\n\n          -  Need to take Warfarin\n\n          -  Presence of rheumatic, degenerative or congenital valvular heart diseases\n\n          -  Early stage or paroxysmal AF\n\n          -  Symptomatic patients with carotid artery disease (such as carotid stenosis>=50%)\n\n          -  Heart failure NYHA grade IV\n\n          -  Recent 30 days stroke or TIA\n\n          -  Presence of active sepsis or endocarditis\n\n          -  Cardiac tumors or other malignancy with estimated life expectancy <2 years\n\n          -  Abnormal blood test; renal disfunction\n\n          -  LAA removed or heart implant patients\n\n          -  Patients have planned electrophysiological ablation or cardioversion 30 days post\n             implantation of the LAmbre system\n\n          -  Patients have history of mechanical prosthesis operation\n\n          -  Patients who are pregnant, or desire to be pregnant during the during the study\n\n          -  Participation in other trials\n\n          -  A known allergy to nitinol\n\n          -  Patients will not be able to complete the trial\n\n        Esophageal ultrasonic exclusion criteria:\n\n          -  LAA Ostium <=12mm or >=30mm\n\n          -  LVEF <30%\n\n          -  Presence of thrombus in the heart\n\n          -  High risk PFO\n\n          -  Mitral valve stenosis (valve area <2 cm2"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "154", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02029014", 
            "org_study_id": "LAA v1.1"
        }, 
        "intervention": {
            "arm_group_label": "LAmbre closure system", 
            "intervention_name": "LAA closure system", 
            "intervention_type": "Device"
        }, 
        "intervention_browse": {
            "mesh_term": "Warfarin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "LAmbre", 
        "lastchanged_date": "March 16, 2014", 
        "location": {
            "contact": {
                "email": "davidliu@coremed.com.cn", 
                "last_name": "David Liu, MD", 
                "phone": "+86 10 6595 6828", 
                "phone_ext": "806"
            }, 
            "facility": {
                "address": {
                    "city": "Wuhan", 
                    "country": "China", 
                    "state": "Hubei", 
                    "zip": "430060"
                }, 
                "name": "People's Hospital of Wuhan University"
            }, 
            "investigator": {
                "last_name": "Congxin Huang, Prof. MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Evaluation of Safety and Efficacy of the New Generation of Left Appendage Closure With the LAmbre Device in AF Patients Not Suitable for Use of Warfarin", 
        "overall_contact": {
            "email": "davidliu@coremed.com.cn", 
            "last_name": "David Liu, MD", 
            "phone": "+86 10 6595 6828", 
            "phone_ext": "806"
        }, 
        "overall_official": {
            "affiliation": "People's Hospital of Wuhan University", 
            "last_name": "Congxin Huang, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Ischemic stroke", 
                "safety_issue": "No", 
                "time_frame": "One year"
            }, 
            {
                "measure": "Successful sealing of the LAA", 
                "safety_issue": "No", 
                "time_frame": "One year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02029014"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "death, thromboembolism, device related complication and MACCE", 
                "measure": "Component events", 
                "safety_issue": "Yes", 
                "time_frame": "One year"
            }, 
            {
                "description": "all-cause death, stroke, cardiac tamponade and renal failure", 
                "measure": "MACCE", 
                "safety_issue": "Yes", 
                "time_frame": "One year"
            }, 
            {
                "measure": "Complication at puncture site", 
                "safety_issue": "Yes", 
                "time_frame": "One year"
            }, 
            {
                "description": "Device migration/embolization Regurgitation Perivalvular leak", 
                "measure": "Device performance assessed by TEE/TTE", 
                "safety_issue": "No", 
                "time_frame": "One year"
            }
        ], 
        "source": "Lifetech Scientific (Shenzhen) Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lifetech Scientific (Shenzhen) Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}